AI Can Detect Lung Nodules that Could Lead to Lung Cancer Nearly 3 Years Before Symptoms & Actual Diagnosis | Study finds

The evidence presented at 2024 World Conference on Lung Cancer highlights chest X-ray AI’s potential to detect lung nodules early and expedite patient care

AI Can Detect Lung Nodules: A new study has been unveiled at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancerin San Diego, CA citing promising initial results using AI-powered chest X-ray interpretation to detect pulmonary nodules which could develop into early-stage lung cancers long before symptoms appear. The retrospective study demonstrated via interim results, an average diagnostic delay of nearly three years from the first abnormal chest X-ray.

The study conducted at the Phrapokklao Hospital’s Cancer Centre of Excellence in Bangkok, Thailand was led by Dr Passakorn Wanchaijiraboon, Medical Oncologist and Deputy Director using the Qure.ai chest X-ray AI solution qXR.

Dr. Passakorn Wanchaijiraboon, while unveiling the poster, said;

“This abstract study, presented at the World Conference on Lung Cancer, provides a snapshot of the significant potential that AI-assisted chest X-ray analysis holds for transforming early cancer detection and reducing the rate of missed lung cancer diagnoses. In most Thai government hospitals, chest X-rays are interpreted by non-radiologists. However, in community hospitals, there are often no radiologists available to read chest X-rays at all. By overlaying specialist AI to read all cases, we can support clinicians in detecting incidental high-risk nodules that may lead to lung cancer. This approach can streamline decision-making and potentially improve patient survival through the earlier diagnosis of cancer. The implementation of CXR AI is particularly beneficial in the context of community hospitals, where it can significantly enhance diagnostic capabilities in the absence of on-site radiologists.” 

The Phrapokklao Cancer Centre study retrospectively reviewed and evaluated the chest X-ray image database of newly diagnosed lung cancer patients over an annual period using qXR. Missed lung cancer was defined as missed in the original report six months prior to a definitive lung cancer diagnosis. 18% of patient cases were found to have a missed lung cancer diagnosis over an average period of nearly three years (32.3 months), with a maximum duration of over eight years (96 months) and minimum eight months. Half the patient cases had chest X-rays taken for non-respiratory symptoms as part of a health check-up, categorising them as ‘incidentally detected’.

Bhargava Reddy, Chief Business Officer, Oncology at Qure.ai

“This is an exciting evidence example that underscores the transformative potential of AI in the fight against lung cancer. Overlaying AI on chest X-rays casts the net wider by proactively triaging patients for the risk of lung cancer. It goes beyond people with symptoms or qualifying for screening initiatives based on age or smoking history, to currently invisible and unprofiled patient populations thus detecting lung cancers earlier.”

Lung Cancer has one of the poorest survival outcomes of all cancers, with over two-thirds of patients diagnosed at an advanced stage, when curative treatment is no longer feasible1. Missed lung cancer is a source of concern for clinicians and an important medicolegal challenge2. Missed nodules resulting from lung cancer are the third most common reason for malpractice claims 3.

IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC24) is being held September 7 to 10 in San Diego, California. The Phrapokklao Cancer Centre study poster abstract presented can be viewed here: https://www.qure.ai/evidence/The-potential-of-chest-X-ray-Al-in-detecting-missed-lung-cancer-diagnosis-in-a-community-based-cancer-center-in-thailand

Ai Can Detect Lung Nodules News
A case of maximum missed lung cancer nodules, diagnosis duration of 97 months
1st image: Prior Chest X ray; 2nd Image: AI result; 3rd Image: Chest X ray at diagnosis
Ct Image At Diagnosis
CT image at diagnosis
Ai Can Detect Lung Nodules
Chest X ray of patient with nodule detected by AI/qXR 23 months prior to the diagnosis of lung cancer. The X-ray was obtained as a part of health check-up.

References

1,2 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338577/

3 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431813/

 

SourceQure.ai

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.